# Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

> **NCT07304232** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 134 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Cell Transplantation (HCT)
- AML (Acute Myeloid Leukemia)

## Interventions

- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT07304232
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07304232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07304232, "Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07304232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*